Tumor‐Associated Monocytes Reprogram CD8 + T Cells into Central Memory‐Like Cells with Potent Antitumor Effects
Advanced Science · 2024-04 · 11 (16)
DOI: 10.1002/advs.202304501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.02.2024. Verfasst von Zeliang Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking …. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Monocytes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shenzhen High-level Hospital Construction Fund and Shenzhen Basic Research Key Project.
Abstract (Originalsprache)
CD8 + T cells are critical for host antitumor responses, whereas persistent antigenic stimulation and excessive inflammatory signals lead to T cell dysfunction or exhaustion. Increasing early memory T cells can improve T cell persistence and empower T cell‐mediated tumor eradication, especially for adoptive cancer immunotherapy. Here, it is reported that tumor‐associated monocytes (TAMos) are highly correlated with the accumulation of CD8 + memory T cells in human cancers. Further analysis identifies that TAMos selectively reprogram CD8 + T cells into T central memory‐like (T CM ‐like) cells with enhanced recall responses. L‐NMMA, a pan nitric oxide synthase inhibitor, can mitigate TAMo‐mediated inhibition of T cell proliferation without affecting T CM ‐like cell generation. Moreover, the modified T cells by TAMo exposure and L‐NMMA treatment exhibit long‐term persistence and elicit superior antitumor effects in vivo. Mechanistically, the transmembrane protein CD300LG is involved in TAMo‐mediated T CM ‐like cell polarization in a cell‐cell contact‐dependent manner. Thus, the terminally differentiated TAMo subset (CD300LG high ACE low ) mainly contributes to T CM ‐like cell development. Taken together, these findings establish the significance of TAMos in boosting T‐cell antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, 100191, China.
- Institute of Precision Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
- Peking-Tsinghua Center for Life Sciences, Peking University Health Science Center, Beijing, 100191, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shenzhen High-level Hospital Construction Fund and Shenzhen Basic Research Key Project
Zitieren
APA
Yang, Z., Liu, L., Zhu, Z., Hu, Z., Liu, B., Gong, J., Jin, Y., Luo, J., Deng, Y., Jin, Y., Wang, G., & Yin, Y. (2024). Tumor‐Associated Monocytes Reprogram CD8 + T Cells into Central Memory‐Like Cells with Potent Antitumor Effects. Advanced Science, 11(16). https://doi.org/10.1002/advs.202304501
Vancouver
Yang Z, Liu L, Zhu Z, Hu Z, Liu B, Gong J, et al. Tumor‐Associated Monocytes Reprogram CD8 + T Cells into Central Memory‐Like Cells with Potent Antitumor Effects. Advanced Science. 2024;11(16). doi:10.1002/advs.202304501
BibTeX
@article{Yang2024,
author = {Yang, Zeliang and Liu, Liang and Zhu, Zhenyu and Hu, Zixi and Liu, Bowen and Gong, Jingjing and Jin, Yuan and Luo, Juan and Deng, Yichen and Jin, Yan and Wang, Guangxi and Yin, Yuxin},
title = {Tumor‐Associated Monocytes Reprogram CD8 + T Cells into Central Memory‐Like Cells with Potent Antitumor Effects},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {16},
doi = {10.1002/advs.202304501}
}
EUVIMED